Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Preclinical and clinical efficacy of MK-767, a dual PPARalpha/PPARgamma agonist

June 17, 2003

DRF-4832 improves hyperglycemia, hyperlipidemia, hypertension and atherosclerosis in animal models

June 17, 2003

Glucose- and triglyceride-lowering effects of a novel pan-PPAR agonist in ZDF rats

June 17, 2003

Niaspan receives U.K. approval

June 17, 2003

Statistically significant imbalance in adverse events in Hemolink trial

June 17, 2003

Azole compounds for diabetes, cancer and lipoprotein disorders claimed by Maxia

June 17, 2003

Heterocyclic PPAR agonists under study at Novartis

June 17, 2003

PTP1B inhibitor IDD-2846 may be useful for improving insulin resistance in diabetes

June 16, 2003

Japanese group characterizes TY-51501 as potential new drug for type 2 diabetes

June 16, 2003

DPP IV inhibition as a strategy for controlling type 2 diabetes

June 16, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...